Company Overview and News

12
An Undervalued Large-Cap Financial Firm You Probably Have Never Heard Of

2018-05-18 seekingalpha
Canadian financial firm Power Corporation of Canada is a holding company with interesting and diverse assets.
BNPQY IGM BNPQF BNPZY GWLOF GWO PWF IGIFF GWO.PR.I GWO.PR.H GWLIF GWO.PR.F GRWTF POFNF

182
North American Financial 15 Split Corp. Regular Monthly Dividend Declaration for Class A & Preferred Share

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- North American Financial 15 Split Corp. (The "Company") declares its regular monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04583 for each Preferred share ($0.550 annually). Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.
MFC.PR.B C.WSA MFC.PR.F MFC.PR.C GS.PRB GS.PRA CIFAF GLSSP GWO JBK TFG GS.PRJ GS.PRI MFC 0945 GS.PRD CGBBW GS.PRC CIX SLFYF GS.PRN GWLIF SLF GS.PRK WFCNP FFN NAF.UN SLF WFC.PRL WFC.PRJ TD WFC.PRT GS C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP SLF.PR.G C.PRU WFC.PRY WFC.PRX TD SLF.PR.B WFC.PRW SLF.PR.E WFC.PRV C.PRS SLF.PR.D WFC WFC.WS TNTTF C.PRL C GSC GS.PRICL C.PRJ C.PRK C.PRG GSJ C.PRC SLF GWLOF C.PRPCL MFC.PR.I MFC.PR.J GWO.PR.I MFC GWO.PR.H MFC.PR.H GJS MFC.PR.M GWO.PR.F MFC.PR.N MFC.PR.K MFC.PR.L

19
Big 8 Split Inc. Announces Quarterly Dividends on Class D Preferred Shares and Class D Capital Shares

2018-05-11 globenewswire
TORONTO, May 11, 2018 (GLOBE NEWSWIRE) -- Big 8 Split Inc. (TSX:BIG.D) (TSX:BIG.pr.D) (the “Company”) announced today that it has declared a quarterly dividend of $0.1125 per Class D Preferred Share. In addition, a quarterly dividend on its Class D Capital Shares was declared of $0.043 per Class D Capital Share. The dividends on both the Class D Preferred Shares and Class D Capital Shares are payable on June 15, 2018 to holders of record on May 31, 2018.
MFC.PR.B SLF MFC.PR.F MFC.PR.C TD GWO SLF.PR.G SLF.PR.B TD SLF.PR.E SLF.PR.D TNTTF SLF MFC 0945 GWLOF MFC.PR.I MFC.PR.J GWO.PR.I MFC GWO.PR.H MFC.PR.H SLFYF MFC.PR.M GWLIF GWO.PR.F MFC.PR.N MFC.PR.K MFC.PR.L SLF

3
Great-West Lifeco, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-04 seekingalpha
The following slide deck was published by Great-West Lifeco, Inc. in conjunction with their 2018 Q1 earnings call.
GWLOF GWO GWO.PR.I GWO.PR.H GWLIF GWO.PR.F

3
BRIEF-Great-West Lifeco Finance (Delaware) LP II Announces Intention To Redeem 7.127% Subordinated Debentures Due June 26, 2068

2018-04-26 reuters
* GREAT-WEST LIFECO FINANCE (DELAWARE) LP II ANNOUNCES INTENTION TO REDEEM 7.127% SUBORDINATED DEBENTURES DUE JUNE 26, 2068
GWLOF GWO GWO.PR.I GWO.PR.H GWLIF GWO.PR.F

3
BRIEF-Great-West Lifeco Subsidiary Irish Life Announces Agreement To Acquire Strategic Holding In Invesco Ltd

2018-04-20 reuters
* GREAT-WEST LIFECO SUBSIDIARY IRISH LIFE ANNOUNCES AGREEMENT TO ACQUIRE STRATEGIC HOLDING IN LEADING INDEPENDENT FINANCIAL CONSULTANCY INVESCO LTD (IRELAND)
GWLOF GWO GWO.PR.I GWO.PR.H GWLIF GWO.PR.F

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...